Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441960 · ClinicalTrials.gov registry record · NA
Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT01441960: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01441960 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441960, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to the brain to produce generalized seizures for the treatment of selected psychiatric disorders such as severe depression. The aim of ECT is to induce a therapeutic tonic seizure where the person loses consciousness and has convulsions. Patients need general anesthesia and neuromuscular blockade to treat pain and avoid excessive tonic clonic motor contraction that might be associated with compression fractures. Neuromuscular blocking drugs (NMBD) are, therefore, administered after induction of general anesthesia to induce neuromuscular blockade. Despite the importance of NMBDs to provide optimal conditions for ECT treatment, the optimal NMBD dose to achieve acceptable neuromuscular blockade without excessive or untoward effects has not previously been identified in any study and in a prospective randomized fashion. The aim of this study is, therefore, to identify the optimal NMBD dose of two commonly used neuromuscular blocking agents (succinylcholine and rocuronium) in order to optimize the muscle strength modulation during ECT that facilitates ECT with the minimal side effects.
Interventions
- DRUG Rocuronium
- DRUG Succinylcholine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441960
The ClinicalTrials.gov registry entry for NCT01441960 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rocuronium is the first listed.
NCT01441960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441960 about?
NCT01441960 is a clinical study titled "Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)". Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to the brain to produce generalized seizures for the treatment of selected psychiatric disorders such as severe depression. The aim of ECT is to induce a therapeutic tonic seizure where the person loses con...
What is the current status of trial NCT01441960?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2011-05. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01441960?
The interventions under investigation include: Rocuronium (DRUG), Succinylcholine (DRUG).
Who is sponsoring clinical trial NCT01441960?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.